Webinar: Trends and Advances in Patient Centric Drug Development

The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts

Overview of capabilities and dosage forms.

Catch up on the latest trends and developments in orally disintegrating tablet (ODT) formulation development

Catch up on the latest trends and developments in patient centric drug development

Directly Compressible 300 μm Granular Mannitol

Creating patient centric dosage forms to enter specialty markets such as orphan drug designation programs and to treat pediatric patients will help to address an emerging industry need for enhancing adherence in patients while providing manufacturers with a successful financial outcome. 

Directly Compressible 160 μm Spray-Dried Mannitol

SPI Pharma has announced an expansion of its line of Mannogem Mannitol products for use in multiple patient-friendly oral dosage forms to now include: Mannogem XL Opal, Mannogem XL Ruby, Mannogem Emerald, and Mannogem Onyx. 

25 μm & 50 μm Powder Mannitol

What is patient centricity? This panel will take a comprehensive look at the definition of patient centricity from varying perspectives within the drug development value chain. From the regulatory, commercial drug formulation, and academic viewpoints, what does patient centricity mean and how do these perspectives feed into the broader meaning of the term? Medical treatment and pharmaceuticals play an essential role in offering quality of life and empowering patients in their care. Currently, oral solid dosage forms are still the most accepted method of delivering drugs to patients within the global pharmaceutical market. Significant market evidence shows patients prefer medicine with a pleasant experience regarding taste and convenient administration. Various patient advocacy groups work to better educate the industry and regulators to more effectively meet patient needs and serve as the patients’ voice. They are often consulted by the pharmaceutical industry to provide feedback in drug delivery options. In more recent years, US regulators have emphasized the focus of patient needs during the drug development process. This session tackles some of the key characteristics, advancements, and developments of patient-centric dosage form design and the critical aspects to improve adherence and acceptance. Watch on-demand now to hear from experts from industry, academia and market intelligence.

Catch up on the latest trends and developments in orally disintegrating tablet (ODT) formulation development.

Watch this webinar featuring Dr Graeme Macleod and Dr Geetha Thanga Mariappan from SPI Pharma, which provides a deep dive into orally disintegrating tablet (ODT) formulation development, as well as an exclusive look at UltraBurst™, the first in class flash ODT platform with disintegration under 10 seconds.

They also show how, by combining UltraBurst technology with SPI Pharma's in-house formulation development capabilities, the company can support customers to design superior flash and conventional ODT systems that have exceptional functionality.

Introducing Mannogem XL Ruby, the latest innovation in granular mannitol from the SPI Pharma Precious Gem Collection. Improve your manufacturing operations, product performance and the patient experience with our high-performing granular mannitol.

Introducing Mannogem XL Opal, the latest innovation in spray-dried mannitol from the SPI Pharma Precious Gem Collection. Improve your manufacturing operations, product performance and the patient experience with our high-performing spray-dried mannitol.

SPI Pharma is the global leader in immediate-relief antacid actives. We specialize in aluminum, magnesium, and calcium products, as well as preformulated solutions for the production of antacid suspensions and tablets.